Denali Therapeutics Q4 2022 net loss $98.7M; cash $1.34B; guides 2023 opex up 25-30%

Denali Therapeutics Inc.

2022-FY EPS reported -$2.60 revenue$108,463,000

Net loss $98.7M in Q4 2022 vs $75.3M in Q4 2021; full year net loss $326.0M vs $290.6M.
Collaboration revenue $10.3M Q4, $108.5M FY2022; R&D expenses $92.1M Q4, $358.7M FY2022.
Cash and marketable securities $1.34B as of Dec 31, 2022; raised $296.2M net in Oct 2022 public offering.
2023 guidance: cash operating expenses expected to increase 25-30% YoY, partially offset by up to $50M in partnership payments.
Phase 2/3 COMPASS study for DNL310 (MPS II) enrolling; Phase 3 LIGHTHOUSE for BIIB122 (Parkinson's) initiated; Phase 2 HIMALAYA for DNL788 (ALS) recruitment completion expected end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Denali Therapeutics Inc. reported financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 27, 2023, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-23-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.